A new approach with the potential to yield a highly selective, safe and effective cancer treatment for both blood cancers and solid tumours.
Our lead asset, STP938 is a first-in-class, highly selective, orally bioavailable, targeted oncology therapy that aims to become a key drug for a multitude of cancer treatment regimens.
Current Cancer Treatment
Every 3 minutes someone is diagnosed with leukemia, lymphoma or myeloma in the US
There are over a hundred different types of blood cancer
No improvement in 5-year survival rates for peripheral T cell lymphoma patients in the past 20 years